IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists. Come discover the science at the premier forum for ID health professionals of varied backgrounds and collaborate, connect and learn from each other’s expertise for the improvement of patient care and public health.
list of files .
|
+—PDF
|Â Â Â Â Q&A.pdf
|Â Â Â Â Case Presentation #4.pdf
|Â Â Â Â Pediatric Case #3.pdf
|Â Â Â Â Pediatric Case #5.pdf
|Â Â Â Â OPAT Overview for APPs.pdf
|Â Â Â Â Case Presentation #7.pdf
|Â Â Â Â Vector-Borne Infections.pdf
|Â Â Â Â Bacterial Syndrome Pearls.pdf
|Â Â Â Â Pediatric Case #2_2.pdf
|Â Â Â Â Case Presentation #6.pdf
|Â Â Â Â Clinical Updates in Infective Endocarditis Presentation, Diagnosis, and Treatment for APPs.pdf
|Â Â Â Â Education and Communication Skills training in Outpatient Settings_3.pdf
|Â Â Â Â Core Elements for Diagnostic Excellence.pdf
|Â Â Â Â Making the Case for Outpatient Stewardship_ Who, Why and How__3.pdf
|Â Â Â Â Parasitic Diseases.pdf
|Â Â Â Â Clinical Topics in General ID.pdf
|Â Â Â Â Interactive Panel_ Moderated by Mary Hayden.pdf
|Â Â Â Â Transplant Infections.pdf
|Â Â Â Â Case Presentation #3.pdf
|Â Â Â Â Outpatient Antibiotic Use, the Core Elements of Outpatient Antibiotic Stewardship and National Stewardship Priorities.pdf
|Â Â Â Â Mycobacteria Including TB.pdf
|Â Â Â Â Pediatric Case #4.pdf
|Â Â Â Â Case Presentation #5.pdf
|Â Â Â Â Antibiotics Overview.pdf
|Â Â Â Â Welcome.pdf
|Â Â Â Â ID Therapeutics_ A Broad Overview.pdf
|Â Â Â Â Common First Targets for Diagnostic Stewardship.pdf
|Â Â Â Â Final Rule on LDTs.pdf
|Â Â Â Â Case Presentation #1.pdf
|Â Â Â Â Case Presentation #2.pdf
|Â Â Â Â TB Epidemiology Overview in the US and Globally.pdf
|Â Â Â Â Pediatric Case #1.pdf
|Â Â Â Â Compensation & Negotiating Your First Contract.pdf
|Â Â Â Â Interactive Panel_ Moderated by Dan Diekema.pdf
|Â Â Â Â ID Mimics_ Noninfectious Causes of Elevated Temperature.pdf
|Â Â Â Â Education and Communication Skills training in Outpatient Settings_1.pdf
|Â Â Â Â Fungal Infections.pdf
|Â Â Â Â Viral Diseases.pdf
|Â Â Â Â Stewarding Bone and Joint Infections.pdf
|Â Â Â Â QI_ Patient Safety Breakout.pdf
|Â Â Â Â Education and Communication Skills training in Outpatient Settings_2.pdf
|Â Â Â Â What Clinicians Should Know About the Lab and What Laboratory Professionals Should Know About Diagnostic Stewardship.pdf
|Â Â Â Â Pediatric Case #2_1.pdf
|Â Â Â Â Non-sputum diagnostics & Diagnostics Pipeline.pdf
|Â Â Â Â Pro_Con Debate Is ESBL Testing Necessary for Ceftriaxone-Resistant Enterobacterales__1.pdf
|    We don’t have what our patients need_ resource limitations in providing care for people with TB in the United States.pdf
|Â Â Â Â Pro_Con Debate Is ESBL Testing Necessary for Ceftriaxone-Resistant Enterobacterales__2.pdf
|Â Â Â Â Stewarding Advanced Diagnostics_ Multiplex Panels, Metagenomics and Beyond.pdf
|Â Â Â Â Antibiotic Stewardship Metrics in the Outpatient Space.pdf
|Â Â Â Â Infection Prevention Update.pdf
|Â Â Â Â Multidrug Resistant Tuberculosis Treatment in the United States_ Tales of relapse and resistance on new short-course regimens.pdf
|Â Â Â Â How to Disagree Better_ Using Advocacy-Inquiry to Improve Communication With Clinicians.pdf
|Â Â Â Â Clinical Updates in Orthopedic ID for APPs.pdf
|Â Â Â Â Making the Case for Outpatient Stewardship_ Who, Why and How__2.pdf
|Â Â Â Â Making the Case for Outpatient Stewardship_ Who, Why and How__1.pdf
|Â Â Â Â Sexually Transmitted Infections.pdf
|Â Â Â Â HIV.pdf
|Â Â Â Â Brain Teasers_ Nervous System Infections and Mimics.pdf
|Â Â Â Â Principles of Diagnosis Excellence & Diagnostic Stewardship.pdf
|Â Â Â Â Career Talk.pdf
|
+—Video Sessions
|Â Â Â Â Session_116_The_Rising_Threat_of_Dengue_and_Other_Arboviruses.mp4
|Â Â Â Â Session_31_Mycology_Matters_Insights_into_Fungal_Infections.mp4
|Â Â Â Â Session_253_Late_Breaker_Abstract_Session_What_s_Going_Viral.mp4
|Â Â Â Â Session_264_Teaching_Clinical_Reasoning_For_The_ID_Educator.mp4
|Â Â Â Â Session_268_Advances_in_Global_Health.mp4
|Â Â Â Â Session_100_New_Antimicrobials_in_the_Pipeline.mp4
|Â Â Â Â Session_200_Revenge_of_the_Syph_ilis_and_Other_Pediatric_Foes.mp4
|Â Â Â Â Session_249_Intricacies_of_CMV_Treatment_and_Prophylaxis_Challenges.mp4
|Â Â Â Â Session_267_Virus_on_the_Brain_Pathogenesis_of_Neurovirulent_Viral_Infections.mp4
|Â Â Â Â Session_252_Inhaling_Insight_Advancements_in_Respiratory_Viral_Infections.mp4
|Â Â Â Â Session_162_Late_Breaker_Abstract_Session_Practice_Changing_Abstracts.mp4
|Â Â Â Â Session_246_Emerging_Issues_With_Influenza_Viruses.mp4
|Â Â Â Â Session_248_Infectious_Endocarditis_Hot_Topics.mp4
|Â Â Â Â Session_265_This_Is_Fine_How_to_Manage_a_Case_of_Mid_Career_Burnout.mp4
|Â Â Â Â Session_72_Ideas_Are_Great_Design_and_Implementation_Are_Better.mp4
|Â Â Â Â Session_33_Challenging_Cases_in_Pediatrics.mp4
|Â Â Â Â Session_243_Steward_Ships_Across_the_Water_Pediatric_AMS_in_the_U_S_and_Europe.mp4
|Â Â Â Â Session_34_Unforgettable_Cases_in_Adult_and_Pediatric_Travel_Tropical_Medicine.mp4
|Â Â Â Â Session_8_Opening_Plenary_Navigating_the_Next_Pandemic_Policy_and_Practice_Integration.mp4
|Â Â Â Â Session_266_Urinary_Tract_Infection_Addressing_New_Findings_.mp4
|Â Â Â Â Session_101_Clinical_Trials_Based_on_Benefit_Risk_An_Open_DOOR.mp4
|Â Â Â Â Session_74_One_Size_Fits_All_Antimicrobial_Dosing_in_Obesity_That_Matters.mp4
|Â Â Â Â Session_83_Challenges_in_Preventing_TB_Disease_Through_LTBI_Treatment.mp4
|Â Â Â Â Session_262_Progress_Not_Perfection_Managing_Substance_Use_Disorders_and_STI_Syndemics_in_HIV_Clinic.mp4
|Â Â Â Â Session_84_Commonalities_and_Differences_in_Antimicrobial_Treatment_of_Resistant_Pathogens.mp4
|Â Â Â Â Session_254_Learning_is_Infectious_Innovations_in_ID_Medical_Education.mp4
|Â Â Â Â Session_88_Thinking_Outside_the_Box_Immunotherapy_for_Immunocompromised_Host.mp4
|Â Â Â Â Session_92_Vaccine_in_Young_and_Old.mp4
|Â Â Â Â Session_86_Let_s_Get_Real_Using_Virtual_and_Extended_Reality_for_Infection_Prevention_Control_Training_and_Education_of_Front_Line_Staff.mp4
|Â Â Â Â Session_205_New_Therapies_for_Bad_Bugs.mp4
|Â Â Â Â Session_120_What_s_Hot_in_Medical_Mycology.mp4
|Â Â Â Â Session_186_Learn_From_the_Experienced_Coffee_and_Cases_in_Resurging_Vaccine_Preventable_Diseases.mp4
|Â Â Â Â Session_20_Maxwell_Finland_Lecture.mp4
|Â Â Â Â Session_30_Emerging_Updates_on_COVID_19_Treatment.mp4
|Â Â Â Â Session_29_Breaking_Ground_ID_Clinical_Trials.mp4
|Â Â Â Â Session_78_Infections_in_Transplant_and_Hematologic_Malignancy_Patients_Part_1.mp4
|Â Â Â Â Session_111_John_F_Enders_Lecture.mp4
|Â Â Â Â Session_108_Prosthetic_Joint_Infections.mp4
|Â Â Â Â Session_91_Intimate_Insights_Sexually_Transmitted_Infection_Studies.mp4
|Â Â Â Â Session_188_Mass_Gatherings_and_Emerging_Infectious_Diseases.mp4
|Â Â Â Â Session_95_Advances_and_Controversies_in_Orthopedic_Infections_A_Multidisciplinary_Discussion.mp4
|Â Â Â Â Session_110_Updates_in_the_Management_of_Leprosy.mp4
|Â Â Â Â Session_170_Influential_Publications_in_Health_Care_Epidemiology_Antimicrobial_Stewardship_Public_Health.mp4
|Â Â Â Â Session_79_Late_Breaker_Abstract_Session_Respiratory_Viruses_Across_All_Ages.mp4
|Â Â Â Â Session_119_Treatment_Conundrums_Not_Always_Black_and_White.mp4
|Â Â Â Â Session_204_HIV_Prevention_Strategies_Solutions_and_Innovations.mp4
|Â Â Â Â Session_255_Tackling_Gram_Positive_Infections_in_Health_Care_Settings.mp4
|Â Â Â Â Session_19_What_s_New_in_Medical_Education_.mp4
|Â Â Â Â Session_80_Topics_in_Pediatric_Antimicrobial_Stewardship.mp4
|Â Â Â Â Session_13_Bronchiectasis_and_NTMs.mp4
|Â Â Â Â Session_152_Big_Beasts_of_Clinical_Mycology.mp4
|Â Â Â Â Session_201_Simplifying_HCV_Diagnosis_and_Treatment.mp4
|Â Â Â Â Session_9_New_ID_Diagnostics_in_the_Pipeline.mp4
|Â Â Â Â Session_181_SHEA_Lectureship.mp4
|Â Â Â Â Session_11_All_Connected_Global_Health_Care_Delivery_and_Product_Development_Impact_on_Domestic_Infectious_Diseases.mp4
|Â Â Â Â Session_69_Changing_the_Vaccine_Narrative_Building_Confidence_Across_the_Lifespan.mp4
|Â Â Â Â Session_118_The_2023_2024_Leaders_in_Epidemiology_Antimicrobial_Stewardship_and_Public_Health_LEAP_Fellowship.mp4
|Â Â Â Â Session_107_Papers_That_Should_Change_Your_Practice_in_Pediatric_ID.mp4
|Â Â Â Â Session_98_Women_in_ID_Breakfast_SHE_for_SHE_A_Masterclass_in_Supporting_Other_Women_in_ID.mp4
|Â Â Â Â Session_121_HAI_Prevention_Bits_and_Bites.mp4
|Â Â Â Â Session_70_Clinical_Metagenomics_Current_State_Opportunities.mp4
|Â Â Â Â Session_28_State_of_the_Art_HIV_Care_and_Prevention.mp4
|Â Â Â Â Session_75_Stories_From_the_Front_Line_of_Adult_Pediatric_Traumatic_Injuries.mp4
|Â Â Â Â Session_187_Manuscript_Peer_Reviews_How_to_Give_Receive_Feedback.mp4
|Â Â Â Â Session_3_Climate_Change_Parasitic_and_Fungal_Diseases.mp4
|Â Â Â Â Session_247_Heroes_of_the_EMR_Computer_Hacks_to_Elevate_Your_Stewardship_Game.mp4
|Â Â Â Â Session_32_Tackling_Gram_Negative_Infections_in_Health_Care_Settings.mp4
|Â Â Â Â Session_114_Climate_Change_and_Infectious_Diseases_A_View_From_the_Melting_Arctic.mp4
|Â Â Â Â Session_166_Friday_With_the_Health_Care_Epidemiology_Pager.mp4
|Â Â Â Â Session_195_A_Global_Approach_to_Identifying_and_Responding_to_Emerging_Infectious_Diseases.mp4
|Â Â Â Â Session_184_Challenging_Cases_in_Patient_Safety.mp4
|Â Â Â Â Session_270_Monitoring_Infections_HAI_Surveillance.mp4
|Â Â Â Â Session_175_Childhood_Pathogens_Cutting_Edge_Research_on_Pediatric_Bacterial_Infections.mp4
|Â Â Â Â Session_6_What_s_Hot_in_ID_HIV.mp4
|Â Â Â Â Session_E_24_PIDS_Member_meeting.mp4
|Â Â Â Â Session_263_Take_It_in_the_Arm_New_and_Evolving_Vaccines_and_Strategies.mp4
|Â Â Â Â Session_185_Inflection_Point_Optimizing_LAI_Patient_Care_and_Program_Features_.mp4
|Â Â Â Â Session_97_Joseph_E_Smadel_Lecture.mp4
|Â Â Â Â Session_112_A_Whole_New_World_Respiratory_Syncytial_Virus_in_the_Vaccine_and_Monoclonal_Antibody_Era.mp4
|Â Â Â Â Session_192_Transplant_ID_101_for_the_General_ID_Practitioner.mp4
|Â Â Â Â Session_173_Viral_Infections_in_Children.mp4
|Â Â Â Â Session_196_Bringing_Health_to_the_Public_Utilizing_Outpatient_Antibiotic_Therapy_Programs_and_Innovative_Care_Models_to_Narrow_Health_Inequity.mp4
|Â Â Â Â Session_17_Should_HCV_Be_Treated_in_Pregnant_Persons_.mp4
|Â Â Â Â Session_2_Acting_on_Poop_Translating_Wastewater_Surveillance_Data_Into_Public_Health_and_Clinical_Action.mp4
|Â Â Â Â Session_24_Emerging_Issues_in_The_Global_Mpox_Threat.mp4
|Â Â Â Â Session_157_Respiratory_Viruses_The_Big_3.mp4
|Â Â Â Â Session_180_Status_Neutral_Squabbles_Should_We_Prioritize_Switching_Suppressed_PWH_to_Two_Drugs_And_Should_We_Ramp_Up_PrEP_Initiation_in_Pharmacies_.mp4
|Â Â Â Â Session_73_Syphilis_in_the_US_It_s_Unrelenting.mp4
|Â Â Â Â Session_18_Stewardship_Metrics_That_Work_How_Prescribing_Practices_Impact_Patient_Outcomes.mp4
|Â Â Â Â Session_4_Infectious_Disease_Stewardship_of_Sepsis_Challenges_and_Opportunities.mp4
|Â Â Â Â Session_273_IDBugBowl.mp4
|Â Â Â Â Session_22_Beyond_the_101_Pondering_Perplexing_Prescribing_Issues.mp4
|Â Â Â Â Session_244_Case_Based_Gu_ID_lines_Adult_Diabetes_Related_Foot_Infections_Pediatric_Acute_Bacterial_Arthritis_and_Antimicrobial_Resistance.mp4
|Â Â Â Â Session_165_Era_of_Resistance_The_Most_Difficult_Gram_Negative_Cases.mp4
|Â Â Â Â Session_1_Gut_to_Be_Important_The_Microbiome_and_Its_Role_in_Neutropenic_Patients_Undergoing_Chemotherapy_and_Stem_Cell_Therapy.mp4
|Â Â Â Â Session_10_AAP_Redbook_Highlights_for_2024_2027.mp4
|Â Â Â Â Session_156_Leveraging_the_Host_Response_for_Infectious_Disease_Diagnosis_and_Pathogen_Discovery.mp4
|Â Â Â Â Session_26_Meeting_Resistance_Novel_Methods_for_Antimicrobial_Resistance.mp4
|Â Â Â Â Session_178_Diagnostic_Clinical_Cases_What_Do_I_Do_With_This_Test_Result_.mp4
|Â Â Â Â Session_82_Challenging_Cases_in_Infectious_Diseases.mp4
|Â Â Â Â Session_89_Advances_in_Health_Care_Associated_C_difficile.mp4
|Â Â Â Â Session_68_Challenging_Consults_in_Mycology.mp4
|Â Â Â Â Session_203_Antimicrobial_Stewardship_Trends_in_Prescribing.mp4
|Â Â Â Â Session_190_The_Cutting_Edge_Top_Research_Papers_in_Medical_Mycology.mp4
|Â Â Â Â Session_191_Tick_Borne_Illnesses_New_Trends_in_Diagnostics_And_Therapeutics.mp4
|Â Â Â Â Session_154_The_Growing_Threat_of_H5N1_on_US_Farms.mp4
|Â Â Â Â Session_174_Beyond_the_Lab_Innovations_in_Diagnostic_Stewardship.mp4
|Â Â Â Â Session_256_Vaccines_and_Their_Impact.mp4
|Â Â Â Â Session_124_Therapy_for_Carbapenem_Resistant_Organisms_in_the_Real_World.mp4
|Â Â Â Â Session_207_Challenging_Cases_in_Transplant_ID.mp4
|Â Â Â Â Session_261_Personalized_Phage_Therapy.mp4
|Â Â Â Â Session_96_Status_Neutral_Squabbles_Weight_Gain_on_ART_Add_a_Weight_Loss_Agent_vs_Switch_ART_And_Should_We_Invest_in_nPEP_as_a_Tool_to_EHE_.mp4
|Â Â Â Â Session_102_HIV_and_Synthetic_Opioid_Use_Additive_or_Synergistic_.mp4
|Â Â Â Â Session_163_Public_Health_Medley_A_Diverse_Mix_of_Topics_and_Trends.mp4
|Â Â Â Â Session_194_Edward_H_Kass_Lecture.mp4
|Â Â Â Â Session_90_Analyzing_Antibiotics_B_Lactam_Therapeutic_Drug_Monitoring.mp4
|Â Â Â Â Session_7_Mano_a_Mano.mp4
|Â Â Â Â Session_182_Stanley_A_Plotkin_Lecture_in_Vaccinology.mp4
|Â Â Â Â Session_257_Afternoon_Delight_Challenging_HIV_and_STI_Co_Infection_Cases.mp4
|Â Â Â Â Session_159_Whole_Genome_Sequencing_Surveillance_for_Infection_Prevention_Promises_and_Barriers.mp4
|Â Â Â Â Session_93_Caroline_B_Hall_Lecture.mp4
|Â Â Â Â Session_94_A_Day_With_the_Stewardship_Pager.mp4
|Â Â Â Â Session_189_Squabbles_Among_Stewards_The_De_Escalation_Debate.mp4
|Â Â Â Â Session_168_Go_With_the_Flow_Infections_and_Mechanical_Circulatory_Support.mp4
|Â Â Â Â Session_117_Let_s_Not_Be_Rash_Infectious_Rashes_and_Their_Mimickers.mp4
|Â Â Â Â Session_202_Translating_Policy_Into_Practice_Experiences_From_the_Field.mp4
|Â Â Â Â Session_208_Challenging_Vaccine_Issues_Beyond_the_Guidelines.mp4
|Â Â Â Â Session_123_Navigating_Acute_Respiratory_Infections.mp4
|Â Â Â Â Session_250_Long_Acting_Lipoglycopeptides_Time_to_Connect_the_Dots_.mp4
|Â Â Â Â Session_176_COVID_19_Epidemiology_Transmission_Vaccine_Updates.mp4
|Â Â Â Â Session_103_How_I_Teach_Frameworks_for_Teaching_Foundational_ID_Topics.mp4
|Â Â Â Â Session_85_Forging_Provider_Public_Health_Partnerships_to_Effect_Control_of_Challenging_Infections.mp4
|Â Â Â Â Session_12_Bills_Bill_Bills_and_ID_What_s_New_and_Exciting_in_Billing_and_Coding.mp4
|Â Â Â Â Session_115_ID_Physician_Compensation_Update_It_s_About_Time_and_Value_.mp4
|Â Â Â Â Session_77_Beyond_the_Virus_HIV_Therapy_and_Co_Morbidities_Research.mp4
|Â Â Â Â Session_105_In_the_Era_of_Shorter_Is_Better_Does_the_Data_Apply_to_My_Immunocompromised_Transplant_Patient_A_Critical_Review_of_the_Evidence.mp4
|Â Â Â Â Session_14_Double_Trouble_Evaluating_Beta_Lactams_as_Adjunctive_Therapy_for_Difficult_Gram_Positive_Infections.mp4
|Â Â Â Â Session_E_6_IDSA_Business_Meeting_Renewed_Priorities_for_a_New_Era_at_IDSA.mp4
|Â Â Â Â Session_76_Strong_Like_Her_Women_and_HIV.mp4
|Â Â Â Â Session_21_I_Don_t_See_Race_The_Impact_a_Colorblind_Constitution_Has_on_Clinical_Disparities_Medical_Education_and_the_Workforce_in_Infectious_Diseases.mp4
|Â Â Â Â Session_15_Peace_of_Mind_Optimizing_Mental_Health_in_the_HIV_Clinic.mp4
|Â Â Â Â Session_167_Develop_Your_Voice_Build_Your_Craft_Writing_to_Impact_Our_ID_Community_and_Our_World.mp4
|Â Â Â Â Session_171_STI_Management_in_Latin_America_and_the_Caribbean_Emerging_Trends_and_Future_Challenges.mp4
|Â Â Â Â Session_269_Infections_in_Transplant_and_Hematologic_Malignancy_Patients_Part_2.mp4
|Â Â Â Â Session_109_Training_the_Next_Generation_New_Infection_Prevention_Curriculum_for_Fellows_From_SHEA_and_AMS_Curriculum_From_SIDP.mp4
|Â Â Â Â Session_260_Group_A_Strep_Familiar_Friend_or_Emerging_Foe_.mp4
|Â Â Â Â Session_25_Managing_Infection_in_the_Era_of_MDR_XDR_and_PDR_Among_Immunocompromised_Hosts.mp4
|Â Â Â Â Session_153_HIV_Updates_for_the_Non_HIV_Specialist_Principles_Pearls_and_Pitfalls.mp4
|Â Â Â Â Session_206_Pediatric_Viral_Studies_Insights_and_Innovations.mp4
|Â Â Â Â Session_272_Special_Session_How_the_Study_Practice_of_Infectious_Diseases_Will_Continue_to_Change_the_World.mp4
|Â Â Â Â Session_199_Just_Enough_or_Way_Too_Much_Is_There_an_Optimal_Duration_of_Therapy_for_Our_More_Complex_Patients_.mp4
|Â Â Â Â Session_158_Surgical_Issues_in_Pediatric_Infectious_Diseases.mp4
|Â Â Â Â Session_164_Tracking_Trends_Insights_into_HIV_Epidemiology_and_Testing.mp4
|Â Â Â Â Session_161_Equity_is_Health_Tackling_Social_Determinants_of_Health_in_ID.mp4
|Â Â Â Â Session_177_Hot_Topics_in_Microbiome_Science.mp4
|Â Â Â Â Session_259_Big_Data_Bad_Bugs.mp4
|Â Â Â Â Session_126_Evolving_Hepatitis_B_Treatment_Guidelines_and_Implications_on_Practice_A_Case_Based_Panel_Discussion.mp4
|Â Â Â Â Session_125_Mind_Blown_Challenging_HIV_Clinical_Cases.mp4
|Â Â Â Â Session_122_Molecular_Diagnostics_in_Clinical_Practice.mp4
|Â Â Â Â Session_179_Clinical_Controversies.mp4
|Â Â Â Â Session_197_Host_Directed_Therapy_Mechanisms_and_Infectious_Complications.mp4
|Â Â Â Â Session_104_ID_Telehealth_Cases_Do_s_And_Don_ts_for_Different_Telecare_Modalities.mp4
|Â Â Â Â Session_193_What_s_on_the_Multiplex_Molecular_Panel_Menu_for_ID_Diagnostics_.mp4
|Â Â Â Â Session_27_Preparing_Your_Hospital_for_the_Next_Big_One.mp4
|Â Â Â Â Session_113_Antimicrobial_Stewardship_Programs_in_Latin_America_and_the_Caribbean.mp4
|Â Â Â Â Session_23_Building_Your_Own_Clinical_Prediction_Model_A_Bootcamp_for_the_ID_Researcher.mp4
|Â Â Â Â Session_160_ASP_Program_Development_and_Evaluation.mp4
|Â Â Â Â Session_271_TB_and_Non_Tuberculosis_Mycobacteria_Updates.mp4
|Â Â Â Â Session_16_Progress_and_Challenges_in_the_Management_of_CNS_Infections.mp4
|Â Â Â Â Session_258_Advancing_the_Management_of_Pediatric_Community_Acquired_Pneumonia.mp4
|Â Â Â Â Session_106_Pandemic_Preparedness_Through_a_Diagnostic_Lens.mp4
|Â Â Â Â Session_71_How_to_Manage_Infectious_Diseases_in_Newly_Resettled_and_Migrating_People.mp4
|Â Â Â Â Session_87_Summer_Fever_Heating_Up_Diversity_in_Infectious_Diseases_at_the_Undergraduate_Level.mp4
|Â Â Â Â Session_251_What_s_New_in_Detection_and_Prevention_of_NTM_Outbreaks.mp4
|Â Â Â Â Session_81_Trials_and_Interventions_to_Improve_Antimicrobial_Stewardship.mp4
|Â Â Â Â Session_245_Clinical_Trials_That_May_Change_Your_Practice.mp4
|Â Â Â Â Session_172_Successful_Stewardship_Strategies_Targeting_Difficult_to_Reach_Prescribers_and_Patient_Populations.mp4
|Â Â Â Â Session_169_Host_Factors_That_Predispose_to_Sepsis_.mp4
|
—Sessions PDF
    180 – Status Neutral Squabbles_ Should We Prioritize Switching Suppressed PWH to Two Drugs_ And Should We Ramp Up PrEP Initiation in Pharmacies__1.pdf
    640 – A County-wide Collaboration to Drive Quality Improvement Using Healthcare-associated Infection Surveillance Data from the National Healthcare Safety Network, Centers for Disease Control and Prevention.pdf
    395 – Using Poetry in Clinical Care and Education.pdf
    610 – Stimulants and HIV.pdf
    300 – Clinical Experience with 16S Ribosomal RNA Gene PCR and Sequencing of Normally Sterile Body Fluids and Tissues in Pediatric Patients.pdf
    369 – Antibiotic Stewardship at a New York City Public Hospital NICU using Neonatal Early-Onset Sepsis Calculator in the Presence of Maternal Chorioamnionitis.pdf
    310 – A comparative study on the effectiveness and safety between colistin-based and high-dose ampicillin_sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetob.pdf
    545 – Sharing European Challenges and Successes in Pediatric Antimicrobial Stewardship_ Europe and the UK.pdf
    415 – Optimizing Blood Culture Utilization in Solid Organ Transplant Recipients_ A Diagnostic Stewardship Approach.pdf
    299 – Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid for Central Nervous System Infections_ Clinical Factors Associated with Increased Diagnostic Yield.pdf
    385 – Sepsis-Associated Encephalopathy and Dementia Outcome_ A Retrospective Cohort Study of 30,378 Adult Sepsis Inpatient Survivors at a Tertiary Medical Center in Taiwan.pdf
    258 – Training the next generation_ New Infection Prevention curriculum from SHEA.pdf
    511 – Activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients in the United States (2023  2024).pdf
    393 – We are Made from Stories_ Narrative Medicine and Finding your Inner Writer.pdf
    174 – Implementation of Methicillin Resistant Staphylococcus Aureus (MRSA) Nasal Polymerase Chain Reaction (PCR) Swabs in Pediatric Patients.pdf
    591 – The Agency for Healthcare Research and Quality (AHRQ) Safety Program for MRSA Prevention_ Impact of an Educational and Implementation Project in United States (US) Hospitals.pdf
    569 – Managing and Preventing NTM Outbreaks_ Hospital Strategies.pdf
    387 – High Rates of Bacteremia and Fluoroquinolone Resistance during an Outbreak of Shigellosis among People Experiencing Homelessness and Opioid Use Disorder in Philadelphia, PA.pdf
    426 – Effectiveness of Updated (2023-2024) Monovalent COVID-19 Vaccines  VISION Network, September 2023-March 2024.pdf
    382 – A Hot Topic_ the Relationship Between Climate Variability and Vector Specific Trends in Tick-Borne Diseases in New Jersey.pdf
    43 – Bronchiectasis Update.pdf
    386 – Pathogen-Harboring Ticks are Prevalent in Suburban Green Spaces in Central North Carolina.pdf
    202 – Targeting Clostridioides difficile Infection Prevention Efforts with Artificial Intelligence.pdf
    627 – Outcomes of Military Blood Donors Screening Positive for Trypanosoma cruzi.pdf
    219 – Robust and Consistent Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) Across Different Age Ranges and Frailty Status in Older Adults.pdf
    514 – The Impact of Xeruborbactam on in vitro Activity of Cefiderocol against a Panel of Acinetobacter baumannii Enriched in Isolates with Reduced Cefiderocol Susceptibility_2.pdf
    362 – Genomic Surveillance_ The Future of Infection Prevention in Hospitals.pdf
    411 – COVID-19 in Children_ Navigating the Current Landscape Amid Vaccine Hesitancy.pdf
    245 – Chronic Pain in People with HIV_ State of the Science.pdf
    220 – A Phase 2 Double-Blind, Placebo-Controlled Study Showing Oral Tableted Norovirus Vaccine VXA-G1.1-NN is Immunogenic, Efficacious, and Reduces Viral Shedding Following Norovirus Challenge.pdf
    287 – Aminopenicillins_ Are they still a treatment option for ampicillin-resistant Enterococcus urinary tract infections_.pdf
    97 – Hemophagocytic Lymphohistiocytosis in Disseminated Histoplasmosis_ an Overlooked Diagnosis.pdf
    277 – Current Epidemiology and Clinical Considerations of Dengue.pdf
    546 – The Antibiotic Prescribing Landscape for Pediatrics in the US.pdf
    223 – PIDS FEATURED ORAL ABSTRACT_ Assessment of Bacterial Pathogens in Young Children with Acute Otitis Media_ A Prospective Cohort Study in the United States (US).pdf
    27 – Plasma microbial cell-free DNA sequencing should be rarely if ever be used as a diagnostic test in the ID clinician s tool kit.pdf
    359 – Re-thinking Regimens and Duration for Peri-Operative Prophylaxis.pdf
    606 – Challenges and Opportunities for Bacteriophage Therapy.pdf
    39 – Anatomy of a Recall_ Outbreaks Due to Product Contamination.pdf
    55 – Educational Scholarship_ Ripe Fruit on the Tree for Success as a Clinician Educator.pdf
    357 – New influenza countermeasures_ What’s coming_.pdf
    621 – Bacterial Mechanisms associated with urinary tract infection.pdf
    227 – Should we invest in post-exposure prophylaxis (PEP) as a tool to end the HIV epidemic_ Pro.pdf
    618 – Burnout Lessons & Renewal, Part 1.pdf
    73 – Viral AMR Detection.pdf
    544 – Sharing European Challenges and Successes in Pediatric Antimicrobial Stewardship.pdf
    248 – ID Telehealth Model #1_ The Access TeleCare Experience.pdf
    187 – Epidemiology of Antimicrobial-Resistant Infections in North America and East Asia.pdf
    601 – Leveraging Big Data from the EHR to Control Transmission of Drug-Resistant Pathogens.pdf
    265 – This just in_ Pediatric and adult RSV immunization policy updates for the 2024-25 respiratory virus season.pdf
    396 – A Drive into the LVAD infections_ approach and management.pdf
    250 – Duration of treatment of Gram-negative bacteremia in immunocompromised patients.pdf
    481 – The Use of Host-Directed Therapy to Address Tuberculosis.pdf
    102 – Carbapenemase producing organisms in Positive Blood and urine Cultures in a large New York Health System Reveals Emergence of NDM-Harboring Organisms and Associated Morbidity and Mortality.pdf
    99 – Impact of Covid-19, Divergent Genomic Modes of Transmission and Strain Replacement of Carbapenem-Resistant Organisms in a Single Hospital in Singapore over 12 years.pdf
    420 – Immunization Impact on Serotype Distribution of Invasive Pneumococcal Disease – Playing the Serotype Whack-A-Mole!.pdf
    549 – IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.pdf
    469 – Coming approaches in the treatment and prophylaxis of tick-borne infections.pdf
    200 – Immunotherapy for mycobacterial and fungal infections.pdf
    477 – Developing Diagnostics for Emerging Infections.pdf
    91 – Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating Pemivibart.pdf
    168 – Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an Investigational Respiratory Syncytial Virus Vaccine, in Participants Aged 2 to _ 18 Years at High Risk of Severe Disease.pdf
    371 – Social Determinants of Vaccine Uptake_ The Impact of Race and Vulnerability on Influenza, SARS-CoV-2, and RSV Vaccination Rates.pdf
    475 – Understanding disease emergence from an ecological perspective.pdf
    543 – The Antibiotic Prescribing Landscape for Children Globally.pdf
    169 – Universal Immunization Strategy Against Respiratory Syncytial Virus (RSV) Prevention in Chile with Nirsevimab during the 2024 Winter Season_ First Southern Hemisphere Nationwide Effectiveness Data.pdf
    584 – Implementation and Evaluation of an Interactive Infectious Diseases Online Curriculum for Trainees on ID electives.pdf
    430 – Tumor microbiota and tumor-infiltrating T cells in the tumor microenvironment of colorectal cancer.pdf
    79 – What’s the latest data and experience on LAI treatment and prevention_.pdf
    84 – Improving Traditional Registrational Trial Endpoints_ Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin-Structure Infections.pdf
    478 – Optimizing Public Health through OPAT.pdf
    499 – Seeing the full picture_ Adding discharge antibiotic durations to the dashboard.pdf
    642 – The Role of Electronic Medical Record Automation in Latent Tuberculosis Screening and Treatment in a Large Health System.pdf
    388 – Co-Testing_ Increasing HIV Testing in Patients Undergoing Sexually Transmitted Infection Evaluation in a Large Integrated Healthcare Network.pdf
    444 – SHEA FEATURED ORAL ABSTRACT_ INSPIRE Trial_ A 92-Hospital Cluster Randomized Trial of INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection versus Routine Antibiotic Select.pdf
    644 – Impact of COVID-19 on Tuberculosis Control and Surveillance_ An 11-Year Retrospective Analysis in Belo Horizonte, Brazil.pdf
    255 – Challengers_ Papers from the past year that may challenge or change your Pediatric ID practice.pdf
    283 – An Assessment of Multi Drug Resistant Organism (MDRO) Reporting Processes in Tennessee.pdf
    126 – Evolving Hepatitis B Treatment Guidelines and Implications on Practice_ A Case-Based Panel Discussion.pdf
    638 – Using NHSN Annual Self-Reported Dialysis Data to Understand Infection Prevention and Control Practices and their Association with Bloodstream Infections in Dialysis Facilities.pdf
    256 – Diagnosis of Periprosthetic Joint Infection.pdf
    188 – Antimicrobial Treatment Guidelines and their Rationale in Japan.pdf
    608 – Clinical Phage Therapy Today_ Stories from the Bedside and Insights from the Lab.pdf
    374 – Early Discontinuation of Empiric Antibiotics for Febrile Neutropenia in Pediatric Allogeneic Haploidentical Hematopoietic Cell Transplant Recipients.pdf
    404 – Influential Publications in Public Health from the Past Year.pdf
    217 – Preliminary Results from a Clinical Trial Comparing the Efficacy of Cefixime Versus Penicillin G for the Treatment of Early Syphilis.pdf
    417 – Should We Be Doing This_ Evaluating Pleural Fluid Inoculation into Blood Culture Bottles..pdf
    468 – New developments in the diagnosis of tick-born infections.pdf
    403 – Influential Publications in Antimicrobial Stewardship from the Past Year.pdf
    259 – Nurturing the Next Generation of Stewards_ A Look Into the SIDP Antimicrobial Stewardship Curriculum.pdf
    100 – Genomic epidemiology of carbapenemase-producing Enterobacter species in Toronto, Canada, 2007-2021.pdf
    157 – Long-Acting Injectable HIV Treatment in Individuals with Adherence Challenges_ Real-World Insights from Southern California.pdf
    183 – Case Presentation # 4.pdf
    270 – Adaptions of microbial populations in the Arctic.pdf
    446 – RSV Vaccine Development_ From Tragedy to a New Era of Vaccinology.pdf
    85 – Improved Survival with Dual Immunomodulator Treatment of ARDS by blocking C5a and IL-6 Activity_ Subanalysis from the PANAMO Study in Critically Ill COVID-19 Patients.pdf
    101 – Patients with Carbapenem-resistant Klebsiella aerogenes and Enterobacter cloacae complex Colonization or Infection Have Different Baseline Characteristics but Similar Mortality and Clinical Outcomes.pdf
    193 – Let s Get Real_ Using Virtual and Extended Reality for Infection Prevention, Control Training and Education of Front Line Staff.pdf
    80 – PEPFAR_ Strategies to accelerate towards ending the epidemic and sustaining the gains.pdf
    435 – Evaluation of Fecal Pharmacokinetics and Metagenomic Changes Following the Administration of Intravenous Omadacycline to Healthy Subjects.pdf
    619 – Burnout Lessons & Renewal, Part 2.pdf
    54 – Not Just Antibiotic Use_ Patient Outcomes Data to Support Stewardship.pdf
    583 – Increasing Diversity, Equity, and Inclusion in the Antimicrobial Stewardship Workforce through the SIDP Certificate Program.pdf
    208 – Exposure-response relationship of ceftazidime_avibactam in adults with central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae_ a prospective observational study.pdf
    7 – Mano-a-Mano.pdf
    171 – Retrospective Review of Management of Acute Otitis Media in a Canadian Pediatric Emergency Department.pdf
    636 – Pneumocystis Pneumonia Outcomes in Solid Organ Transplant Recipients and Patients Living with HIV_ A Population-Based Study Over 20 Years (2002-2022) in Ontario, Canada.pdf
    297 – Comparative In Vitro Microbiologic Activity of Two Antimicrobial Intravenous Connectors.pdf
    425 – Revealing Seasonal Patterns in the Post-Pandemic Era_ A Comparative Analysis of Burden and Seasonality of Influenza and COVID-19 in Europe and the US..pdf
    589 – Late Onset Invasive Group B Streptococcal Disease Outbreak in a Neonatal Intensive Care Unit Identified Through Whole Genome Sequencing  Connecticut, 2020 2024.pdf
    496 – Mask or Not to Mask_ Approaches to Source Control During Respiratory Virus Season in Acute Care Hospitals.pdf
    Introduction.pdf
    570 – Post-Outbreak Management_ Monitoring Clinical Response and Patient Outcomes.pdf
    130 – Pregnant or Breastfeeding_ Vaccines_.pdf
    127 – Fungal Endocarditis_ Diagnosis and Management.pdf
    211 – Defining Optimal Sampling Times for Cefepime Therapeutic Drug Monitoring in Clinical Practice.pdf
    628 – Geographic distribution of hospitalized severe malaria cases in the United States, 2012 2018.pdf
    427 – Underlying Medical Conditions and Vaccination Status among U.S. Children Aged =17 Years Hospitalized for COVID-19 in COVID-19-Associated Hospitalization Surveillance Network (COVID-NET), January Decem.pdf
    178 – Elevating Infectious Diseases Management_ Impact of an Inpatient Pharmacist-Led Tele-Antimicrobial Stewardship Program Integrated within a Health System.pdf
    575 – Safety and Immunogenicity of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults_ Interim Results of a Phase 1_2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial.pdf
    555 – What Happened to Influenza B_Yamagata and How Does This Impact Vaccine Composition_.pdf
    593 – Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of the Safety of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine.pdf
    304 – Global Incidence of Viral Lower Respiratory Tract Disease (LRTD) Episodes and Hospitalizations (2010 2021).pdf
    607 – Therapeutic Phage Monitoring_ Application in Children.pdf
    293 – Association of a Hospital Stress Indicator with Device Associated Infections.pdf
    264 – RSV in adults_ Epidemiology of severe RSV disease and RSV vaccines in the first year.pdf
    389 – Trends in HIV-Related Mortality Among Reproductive-Aged Women in the United States.pdf
    247 – Effective Incorporation of Health Equity Education Into ID Teaching.pdf
    645 – Rapid Versus Conservative Tuberculosis De-isolation Policy Impact Assessment_ Province-wide Retrospective Review of 2017-2020, British Columbia, Canada.pdf
    93 – Biomarkers of Amphotericin-Induced Complement Activation and Associated Clinical Manifestations.pdf
    514 – The Impact of Xeruborbactam on in vitro Activity of Cefiderocol against a Panel of Acinetobacter baumannii Enriched in Isolates with Reduced Cefiderocol Susceptibility_1.pdf
    464 – De-escalation is the Cornerstone of Stewardship.pdf
    156 – A Quality Improvement Pilot to Increase Hepatitis B Screening and Optimize Patient Selection for Switch to Two-Drug Antiretroviral Regimens in Patients with HIV.pdf
    206 – A Cluster Randomized Trial Evaluating Universal Gloving for Reducing Clostridioides difficile Acquisition and Infection in VA_ The GloRI Study.pdf
    488 – Therapy for UTIs in Kidney Transplant Recipients and Other Vulnerable Patients.pdf
    480 – The Future is at Home.pdf
    473 – Future Directions for Multiplexed Infectious Disease Panel Testing.pdf
    267 – Determinants of misuse of antibiotics in hospitals.pdf
    176 – A Quality Improvement Endeavor to Improve Antibiotic Prescribing for Children with Acute Otitis Media in Emergency and Urgent Care Settings.pdf
    35 – Pathogen Whole Genome Sequencing for Rapid ID & AST Directly from Multiple Clinical Sample Types.pdf
    81b – Update on Lenacapavir for PrEP_ Results from the Interim Analyses of PURPOSE 1 and PURPOSE 2.pdf
    94 – A Day With the Stewardship Pager.pdf
    466 – Top Research Papers_ Molds and Dimorphic Fungi.pdf
    194 – Here s a (VR) App for That_ Addressing Human Factors via Headsets & Beyond.pdf
    406 – PrEP and Treatment of HIV in LATAM.pdf
    214 – Clinical Characteristics and Outcomes of Patients Treated with Tecovirimat for Mpox Disease_ A Large Cohort in New York City.pdf
    445 – Musings on Growing the Next Generation of Healthcare Epidemiologists.pdf
    507 – Trajectories of Newly Initiated Pre-Exposure Prophylaxis (PrEP) Use among Priority Populations with Unmet Needs for PrEP in the USA.pdf
    517 – Maternal RSV Vaccination and Infant Nirsevimab Coverage among Infants Born in the 2023-2024 Respiratory Virus Season in a Large Integrated Healthcare System.pdf
    253 – National Response Testing Framework for Partner Coordination.pdf
    457 – Experienced Perspectives in VPD Part 1.pdf
    180 – Status Neutral Squabbles_ Should We Prioritize Switching Suppressed PWH to Two Drugs_ And Should We Ramp Up PrEP Initiation in Pharmacies__2.pdf
    29 – Presentation #1.pdf
    306 – Patient-Derived Airway Organoids_ a Pre-clinical Platform to Model RSV Infection.pdf
    375 – Back to School Unequal_ Neighborhood Disadvantage and Asthma-related Emergency Department Visits in School-Aged Children.pdf
    192 – Controlling the regional spread of MDROs.pdf
    380 – Implementation of Pooled Saliva Tests for Universal Screening of Congenital Cytomegalovirus (cCMV) Infection_ Lessons Derived Over a 25-Months Period.pdf
    262 – Human Infections with Highly Pathogenic Avian Influenza A(H5N1) Viruses and Pandemic Influenza Threats.pdf
    470 – Review of infection prevention strategies for HCT and CAR-T cell therapy recipients.pdf
    586 – Let’s Have a Chat_ How Well Does an Artificial Intelligence Chatbot Answer Clinical Infectious Diseases Questions_.pdf
    263 – RSV prevention in infants_ Use and impact of maternal vaccines and infant monoclonal antibodies.pdf
    140 – Overcoming Barriers in the Implementation of Evidence-Based Strategies to Reduce the Risk of Surgical Site Infections.pdf
    49 – Review of Progress and Challenges in Bacterial Meningitis and Encephalitis.pdf
    474 – An Innovative Approach of a New Era of Social Justice_ The Triple Threat!.pdf
    632 – Cytomegalovirus Infections in Patients with Relapsed_Refractory Multiple Myeloma on Novel T-Cell Redirecting Therapy.pdf
    370 – Swimming Against the Current_ Outcomes of Standard versus Modified Outpatient Parenteral Antimicrobial Therapy (OPAT) Services.pdf
    199 – Helping the Host before things Go Viral_ Immunotherapy of Viral Infections.pdf
    180 – Case Presentation #1.pdf
    216 – Effectiveness of JYNNEOS Vaccination in Preventing Lesion Dissemination Among Individuals with Confirmed Mpox Infection.pdf
    95 – Advances and Controversies in Orthopedic Infections_ A Multidisciplinary Discussion.pdf
    90 – Impact of anti-CD20 therapy on COVID-19 in immunocompromised patients_ A nationwide cohort study in Korea.pdf
    379 – Potential clinical and economic impact of cutbacks in the United States President’s Emergency Plan for AIDS Relief Program in South Africa_ a modelling analysis.pdf
    95 – Novel Antifungal Olorofim Use in Intractable CNS and Non-CNS Disseminated Coccidioidomycosis.pdf
    428 – Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission during the Omicron Era in Massachusetts_ A Prospective, Case-Ascertained Study using Genomic Epidemiology.pdf
    565 – Emergency and outpatient implementation of Dalbavancin use.pdf
    239 – Fosmanogepix, Basilea Pharmaceutica International Ltd, Allschwil (Switzerland).pdf
    423 – Mirror Mirror on the Wall Who is Driving all the Invasive GAS After All – The Utah Experience.pdf
    20 – What’s Hot in ID Basic Sciences.pdf
    560 – Percutaneous Mechanical Aspiration or Surgical Resection.pdf
    33 – Challenging Cases in Pediatrics.pdf
    136 – Screening algorithms to identify latent and subclinical infections in newly resettled populations.pdf
    390 – HIV Mortality Trends among the United States Population from 1999-2023_ A Retrospective Study using the CDC Wonder Database..pdf
    132 – Clinical Metagenomics_ Current State & Opportunities.pdf
    620 – Burnout_ Lessons & Renewal, Part 3.pdf
    603 – Group A Streptococcus_ Molecular Pathogenesis of Invasive Infection and Efforts Toward a Preventative Vaccine.pdf
    383 – VA SHIELD_ Building an Interactive Dashboard for Surveillance of Infectious Diseases across the Veterans Health Administration, 2000  2023.pdf
    37 – AAP Redbook_ Highlights for 2024-2027 Part 2.pdf
    242 – Implementing DOOR in Registrational Antibacterial Trials.pdf
    476 – Climate Change and Emerging Infectious Diseases- A Clinical Approach.pdf
    553 – The Public Health Threat of Highly Pathogenic Avian Influenza A(H5N1) Viruses.pdf
    94 – Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections.pdf
    151 – HIV Prevention for Black Cis-Gender Women in the US.pdf
    479 – Strategies for designing equitable OPAT programs.pdf
    399 – Cytokines and Systemic Inflammation During Neonatal Sepsis.pdf
    580 – Pharmacokinetics (PK) and Safety of Nirmatrelvir_Ritonavir (NMV_r) in Non-Hospitalized Symptomatic Pediatric Patients Ages 6 Years and Older with COVID-19 who are at Increased Risk of Progression to S.pdf
    616 – Teaching Clinical Reasoning on the Wards & in the Clinic.pdf
    288 – How should I select antibiotic agents for the treatment of diabetic foot infections_.pdf
    295 – Methods for Cost-efficient Real-time Whole Genome Sequencing Surveillance for Enhanced Detection of Outbreaks in a Hospital Setting.pdf
    432 – High-fat diet changed Salmonella infection patten associated with increasing intestinal permeability and altering gut microbiota.pdf
    56 – Teaching ID by Podcast.pdf
    69b – Challenging Issues in Mpox Vaccination.pdf
    461 – Your Manuscript has Comments_ What Next_.pdf
    402 – Influential Publications in Healthcare Epidemiology from the Past Year.pdf
    51 – What We Know So Far.pdf
    236 – Zoliflodacin_ Addressing a growing global threat through a novel public-private development partnership.pdf
    173 – Identifying Opportunities for Urine Culture Diagnostic Stewardship in a Pediatric Health System.pdf
    354 – Host biomarker tests for distinction of bacterial versus viral infection_ overview and clinical case study.pdf
    70 – The impact of antimicrobial resistance in patients with hematological malignancies and hematopoietic stem cell transplant recipients.pdf
    573 – CD388, a Novel Drug-Fc Conjugate (DFC), Demonstrates Prophylactic Activity in an Influenza Human Challenge Model.pdf
    551 – Clinical Trials in Viral Diseases that may Change your Practice.pdf
    421 – Acute Rheumatic Fever at a US Children’s Hospital During a Period of Fluctuating Group A Streptococcus Incidence.pdf
    312 – Impact of Patient Subgroups on the Efficacy of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C_T) for Multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CAC.pdf
    483 – Host-Directed Interventions Against Malaria.pdf
    624 – HSV Encephalitis and Neuropathogenesis of HSV infection.pdf
    139 – Back to the Basics_ Ensuring Infection Prevention Practices are Happening the Way They Should.pdf
    40 – Case based discussion on optimizing billing and coding to impact reimbursement and quality metrics.pdf
    83 – Predictors of Undetectable HDV RNA 48 weeks after completion of finite treatment with Bulevirtide and Pegylated-Interferon Alpha 2a.pdf
    145 – Obesity Dosing in Antibacterials.pdf
    305 – Hospitalized Patients with Community-Acquired Pneumonia and Structural Lung Disease_ A Multicenter Analysis.pdf
    465 – Spectrum De-escalation_ Is the experiment over_.pdf
    613 – A new vaccine for an ancient plague_ development of a schistosomiasis vaccine.pdf
    5 – Using wastewater to track diseases with limited public health surveillance data.pdf
    47 – Utilizing Clinic-based Interventions to Re-engage the Struggling Patient.pdf
    490 – No Time to Lues_ Evaluation & Management of Congenital Syphilis in the Exposed_Infected Infant.pdf
    58 – How Did We Get Here__ How Law Impacts Population Health & Clinical Disparities in ID.pdf
    226 – Weight gain on ART_ Add weight loss agent.pdf
    266 – Advancing Antimicrobial Stewardship_ Strategies for Optimizing Containment of Antimicrobial Resistance in Latin America and the Caribbean.pdf
    254 – Challengers_ Papers from the past year that may challenge or change your Pediatric ID practice.pdf
    38 – Medical Tourist Beware! A Review of Recent Outbreaks Related to Medical Tourism.pdf
    513 – Cefiderocol Retains in vitro Activity Against Enterobacterales Non-Susceptible to -lactam- -lactamase Inhibitor Combinations.pdf
    301 – Clinical impact of a Streptococcus pneumoniae PCR assay on pleural fluid specimens for children with complicated pneumonia.pdf
    597 – Emerging Diagnostic Testing and Risk Stratification for Pediatric Community-Acquired Pneumonia.pdf
    373 – Closing Care Gaps_ Optimizing Pre-Transplant Trypanosoma cruzi Testing.pdf
    368 – Impact of Social Determinants of Health (SDOH) on Outcomes of OPAT (Outpatient Parenteral Antimicrobial Therapy).pdf
    243 – Unlocking Insights_ A DIY Guide to Conducting DOOR Analysis with Your Own Dataset.pdf
    617 – Incorporating Clinical Reasoning into Case Conferences.pdf
    365 – Amoxicillin Direct Oral Challenge in Patients with High-Risk Allergic Reaction.pdf
    221 – Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) when Co-administered with Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US and Puerto.pdf
    487 – Therapy for patients with complex pulmonary syndromes such as empyema.pdf
    45 – Beta-Lactam Adjunctive Therapy for Difficult Staphylococcus aureus Infections.pdf
    87 – Machine Learning-Guided Generation of a Potent Combination of Broadly Neutralizing Sarbecovirus Antibodies with a High Barrier to Resistance.pdf
    69a – Alternative Antiviral Therapies for Treating Severe Mpox Infection.pdf
    590 – Impact of Universal Nasal Decolonization with an Alcohol-Based Nasal Antiseptic (ABNA) Versus Mupirocin on Infection Rates and Antimicrobial Utilization in Patients (Pts) Admitted to the Burn Service.pdf
    62 – Do we still need to treat group A streptococcal pharyngitis for 10 days_.pdf
    576 – Chandipura virus infection_ Time to think beyond Encephalitis_.pdf
    203 – Screening and Targeted Prophylaxis for Clostridioides Difficile Infection_ STOP-CDI.pdf
    405 – The Challenges in STI management in Latin America.pdf
    22 – Amoxicillin should be used as first line treatment of acute sinusitis.pdf
    298 – Host Response Profiling from Clinical Metagenomic Sequencing Data for Diagnosis of Central Nervous System Infections.pdf
    313 – Genomic Features Associated with Non-susceptibility to Cefiderocol in Pseudomonas aeruginosa and Cross-resistance to Novel -lactam_ -lactamase Inhibitors in the Prospective Observational Pseudomonas .pdf
    290 – Emerging Fungal Infections.pdf
    129 – Vaccine confidence_It s not just for kids!.pdf
    398 – Dosing Antimicrobials in Patients Requiring Mechanical Circulatory Support.pdf
    505 – Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis_ Data from Trio Health Cohort.pdf
    96 – Candida albicans bloodstream infections are comprised of diverse populations of strains, including antifungal tolerant strains that emerge during treatment failure.pdf
    244 – The impact of synthetic opioids on HIV viral transmission and kinetics_ Lessons from the bench.pdf
    631 – Cost-effective diagnostic algorithms for Ugandan patients with solid tumors who develop chemotherapy-associated febrile illness.pdf
    2 – The role of the mycobiome in hematopoietic cell transplantation outcomes.pdf
    294 – Assessment of Disinfectants for Reducing Candida auris Burden on Needleless Connectors_ an In Vitro Study.pdf
    147 – Antifungal Dosing for Patients with Obesity.pdf
    419 – Changing Epidemiology of Pediatric Invasive Group A Streptococcus Infections in the United States, 2004-2022.pdf
    191 – Public health efforts to improve hepatitis C care and treatment in Los Angeles.pdf
    572 – The Burden of RSV Infections Among Nursing Home Residents, Monroe County, NY, October 2022 to April 2023.pdf
    378 – Visby Medical Women s Sexual Health Test_ An Over-the-Counter Molecular Diagnostics Solution to STI Testing _The Visby Medical Women s Sexual Health test has not been cleared or approved by the FDA fo.pdf
    392 – Antiretroviral Prophylaxis to Prevent Perinatal HIV Infection in Medicaid-Insured Infants, 2009-2021.pdf
    397 – Emo about ECMO_ Addressing Infectious Challenges.pdf
    59 – Achieving Health Equity by Creating Diversity in the era of a Colorblind Constitution.pdf
    205 – Utilization of the Four Themes of the CDC_ATSDR SVI Interactive Map in Assessing Initial Clostridioides difficile Infection Outcomes.pdf
    46 – Beta-Lactam Adjunctive Therapy for Difficult Enterococcal Infections.pdf
    635 – Do Necrotizing Soft Tissue Infections Behave Differently in Patients with Hematological Malignancies_ A Propensity Score-Matched Retrospective Cohort Study in an Oncological Center in Mexico City.pdf
    286 – Quantifying the Environmental Impact of MRSA_VRE Contact Precautions in Los Angeles County.pdf
    614 – Update on Dengue Vaccines.pdf
    78 – The Bioethics of Caring for a patient with a Special Pathogen_ family-centered care and beyond.pdf
    623 – The Call is Coming from Inside the House_ the Gut Microbiome as Reservoir for Antimicrobial Resistance.pdf
    65 – Prediction Models 101_ The Models.pdf
    268 – Role of pharmacists in antimicrobial stewardship programs in LATAM.pdf
    278 – Advances in Dengue Prevention_ New Insights and Challenges for Vaccination and Vector Control.pdf
    309 – Detection of hemagglutinin H5 influenza A virus sequence in municipal wastewater solids during an outbreak of avian influenza.pdf
    307 – Respiratory Syncytial Virus (RSV) Infections Among Persons Aged 60 Years and Older, by Vaccination Status, reported via Electronic Laboratory Reporting (ELR)  Los Angeles County (LAC), California.pdf
    155 – Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1_ 3-Year Results of the CAPELLA Study.pdf
    66 – Prediction Models 101_ The Implementation and Automation.pdf
    594 – A Phase I, Multicenter, Randomized, Double-blind, Placebo-controlled Single Dose, Dose-ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Orally Administered Bivalent GI.1_GII.4.pdf
    41 – Coding For Our Value–ID Complex Care.pdf
    92 – Obeldesivir Reduced SARS-CoV-2 Infectious Titers in the BIRCH Phase 3 Clinical Trial.pdf
    615 – Best Practices in the Undergraduate Classroom.pdf
    182 – Case Presentation #3.pdf
    567 – Dalbavancin as an option for treatment of S. aureus bacteremia.pdf
    72 – Quinolone prophylaxis_ a double-edged sword_.pdf
    172 – Impact of 24_7 Rapid Diagnostic Testing Pharmacist Interventions and Infectious Diseases Consultation in Pediatric Staphylococcus aureus Bacteremia.pdf
    165 – Era of Resistance_ The Most Difficult Gram-Negative Cases.pdf
    343 – Cutting Edge ART in 2024.pdf
    179 – Clinical Controversies.pdf
    314 – Ceftazidime-Avibactam Versus Meropenem-Vaborbactam for the Treatment of Carbapenem-Resistant Enterobacterales Infections.pdf
    26 – Plasma microbial cell-free DNA sequencing should be routinely used as a diagnostic test in the ID clinician s tool kit.pdf
    272 – Special Session_ How the Study & Practice of Infectious Diseases Will Continue to Change the World.pdf
    184 – Case Presentation # 5.pdf
    578 – Metformin reduces the risk of Long COVID or Death over 6 months in an Emulated Target Trial of Primarily Omicron-infected Adults without Diabetes or Prediabetes_ a New-User, Active-Comparator Analysis.pdf
    401 – Sepsis and the Microbiome.pdf
    641 – Real-Time Whole Genome Sequencing Surveillance of Healthcare Associated SARS-CoV-2, Respiratory Syncytial Virus (RSV) and Influenza.pdf
    10 – Leishmania immunopathology and climate impact on Leishmaniasis.pdf
    626 – PML_ Pathogenesis and risks in the current era of immunosuppression.pdf
    218 – Attenuated PreFusion F Antibody Response to RSV Vaccines in Solid Organ Transplant Recipients.pdf
    213 – Electronic Visit (E-visit) Use for Sexually Transmitted Infection (STI) Testing in a Large Integrated Healthcare System.pdf
    558 – The Epic Challenge of Optimizing Antimicrobial Stewardship.pdf
    34 – Deepull_ Ullcore BSI test – One hour direct-from-blood multiplex PCR targeting 95% of sepsis-causing pathogens and select resistant markers.pdf
    629 – Evaluation of Neurocysticercosis Healthcare Provider Diagnostic Practices in Houston, Texas.pdf
    238 – AIC468 – a first-in-class antiviral antisense oligonucleotide for the treatment of BKV infection in kidney transplant recipients.pdf
    165 – Real-world Abrysvo Vaccine Effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related Severe Acute Respiratory Infection (ARI) Hospitalizations and Emergency Department (ED) Visits Kaiser Pe.pdf
    634 – Association of pre-transplant CD4 count on post-renal transplant infectious outcomes among persons with HIV.pdf
    577 – Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir.pdf
    646 – Clinical and microbiological outcomes of omadacycline for pulmonary Mycobacterium abscessus complex.pdf
    360 – Where are we with management of pediatric spinal hardware infections_.pdf
    414 – Culture Clash_ A Comparison of Approach to Blood Culture Diagnostic Stewardship across 3 Emergency Departments in a Healthcare Network.pdf
    88 – Efficacy of nirmatrelvir-ritonavir in high-risk trial participants with prior SARS-CoV-2 infection or vaccination_ a pooled analysis.pdf
    311 – Defining the magnitude of desirability of outcome ranking (DOOR) differences in effectiveness of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C_T) for multidrug-resistant (MDR) Pseudomon.pdf
    377 – Impact of VE303, a Defined Bacterial Consortium, on Antimicrobial Resistant Gene Prevalence in Patients with Clostridioides difficile Infection (CDI).pdf
    381 – Transplantation of Maternal Intestinal Flora to the Newborn After Elective Cesarean Section – A Randomized Controlled Trial (SECFLOR).pdf
    552 – Clinical Trials in Fungal Diseases that may Change your Practice.pdf
    159 – Transplant Transmitted Infectious Among Recipients of Drowned Donor Organs_ A Six Year DTAC Experience.pdf
    98 – Multispecies Outbreak of Klebsiella pneumoniae Carbapenemase-3 (KPC-3)-producing Enterobacterales in an Acute Care Hospital  Virginia, 2023-2024.pdf
    296 – MDR Risk Index_ Multidrug-Resistant Bacteria Probability Score for General Hospitals.pdf
    518 – Newborn immune transcriptome changes rapidly and is shaped by maternal SARS-CoV-2 infection and_or vaccination.pdf
    361 – When and How Often Do We Need to Debride_ ENT Management of Invasive Fungal Sinusitis in Children.pdf
    453 – Prevention of Infection in Immunocompromised Hosts_ Common, Yet Complicated Cases.pdf
    611 – Meeting People Where They Are_ Field Based Testing and Treatment for STIs in Los Angeles County.pdf
    128 – Fungal Disease of The Urinary System.pdf
    67 – Global Epidemiology of Mpox in 2024.pdf
    341 – Coccidioidomycosis_ new thoughts on ecology, epidemiology, diagnosis, and treatment.pdf
    229 – IDSA FEATURED ORAL ABSTRACT_ MVA-BN Induces a Low Avidity, Non-Durable Humoral Response Against Mpox Virus.pdf
    61 – Three days of antibiotics for uncomplicated community-acquired pneumonia_ Ready for prime time_.pdf
    562 – Progress and Opportunities_ CMV Prevention.pdf
    126 – Ocular Fungal Infections.pdf
    500 – Finding AP Gap_ An Assessment of Antibiotic Use in Acute Pancreatitis.pdf
    81 – Treatment and prevention pipeline_ What’s coming_.pdf
    587 – Impact of the infectious site infection with Staphylococcus aureus in Europe_ results from the economics of the SALT study.pdf
    18 – What’s Hot in HIV Basic Sciences.pdf
    73 – Clinical Conundrums in Syphilis Management.pdf
    554 – Other Emerging Influenza Viruses with Species Crossover Potential.pdf
    516 – Cytomegalovirus (CMV) Saliva Shedding Kinetics in Children with Congenital Cytomegalovirus Infection (cCMV)..pdf
    408 – Working with Surgical Teams to Support Stewardship.pdf
    460 – A Systematic Approach to Manuscript Appraisal.pdf
    284 – Antibiotic Allergies in Long-Term Care Settings in Massachusetts_ Current State and Paths Forward.pdf
    581 – Enhancing Diversity, Equity, Inclusion, Access, and Justice (DEIAJ) Teaching in Infectious Diseases_ Current State and Future Directions in Faculty Development.pdf
    566 – Inpatient use of Oritavancin for difficult-to-treat infections.pdf
    148 – Approach to Bacterial Infections after Conflict Trauma and Burn Injuries.pdf
    63 – Daptomycin and statins_ To hold or not to hold.pdf
    489 – Therapy for invasive candidiasis.pdf
    596 – Immunogenicity and Safety of BPZE1, an Intranasal Live Attenuated Pertussis Vaccine, Evaluated With and Without Tdap in Healthy Children 6 to 17 Years Old_ A Phase 2b, Randomized, Active-Controlled St.pdf
    561 – IVDU-associated IE antibiotic treatment.pdf
    508 – Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP)_ Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort.pdf
    222 – Effectiveness of the Original BNT162b2 Messenger RNA Vaccine Against COVID-19 Omicron Infection in Children Aged 6 Months to 4 Years in Japan.pdf
    158 – Hepatitis B Screening Among Persons With HIV Receiving Care from the U.S. Department of Veterans Affairs.pdf
    502 – Epidemiology and Outcomes of Broad-Spectrum Antibiotic De-escalation in Patients with Suspected Sepsis in US Hospitals.pdf
    564 – Congenital CMV_ A rapidly changing field.pdf
    394 – Narrative Medicine as a Method for Deep Engagement with Self, Other, and System.pdf
    497 – Little patients, big changes_ Strategies to implement the 2024 NHSN Pediatric HAI Definitions.pdf
    548 – Acute Bacterial Arthritis in Kids_ The first IDSA_PIDS Guidelines have finally arrived.pdf
    494 – Further simplification of HCV treatment.pdf
    175 – Concordance of UTI Antibiotic Treatments with Facility-Specific Antibiograms in Nursing Homes.pdf
    416 – Impact of clinical diagnostic stewardship of respiratory cultures across a multicenter PICU collaborative.pdf
    133 – Clinical Metagenomics_ Leveraging clinical impact.pdf
    204 – Clostridioides difficile screening among asymptomatic carriers admitted for bone marrow transplantation_ Navigating optimal stewardship strategies.pdf
    315 – Modeling Strain-Dependent Variability in Carbapenem-Resistant Klebsiella pneumoniae Colonization in the Malnourished Host.pdf
    563 – Treating refractory CMV in difficult cases.pdf
    210 – Implementation of a Pharmacist Driven Beta-lactam Therapeutic Drug Monitoring Program with Daily Result Reporting_ Initial Experiences and Challenges Faced.pdf
    471 – Review of management strategies for SOT recipients.pdf
    344 – HIV Primary Care_ Modern Challenges and Guideline Update.pdf
    7 – From Toilet to Bedside_ How Wastewater Surveillance Can Be Leveraged For Clinical Consideration.pdf
    207 – Challenging Cases in Transplant ID.pdf
    76 – The Big Picture_ Our National Framework For Caring For Patients With Special Pathogens..pdf
    86 – The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO)_ the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD122.pdf
    434 – Reduced Gut Microbiome Diversity and Compositional Characteristics are Associated with Postoperative Infection in Heart Transplant Recipients.pdf
    186 – Less is More_ Shortening TB Preventive Therapy.pdf
    292 – Comorbidities and Fungal Disease Beyond Immunosuppression_ A Global View.pdf
    568 – Characterizing NTM Outbreaks Using Epidemiology and Genomics.pdf
    491 – Care of Infants with Inadequate Maternal Prenatal Care.pdf
    237 – Clarametyx Biosciences, CMTX-101.pdf
    257 – Prosthetic Joint Infections.pdf
    71 – Is it time to re-design the empiric antibacterial approach in febrile neutropenia_.pdf
    153 – Global HIV in Women and Children_ Progress and Challenges.pdf
    181 – Case Presentation #2.pdf
    585 – Effects of Legislation Restricting Reproductive and LGBT+ Rights on Infectious Disease Fellowship Match Rates.pdf
    163 – Novel Factors Predicting Mortality in Allogeneic Hematopoietic Cell Transplantation Recipients with Viral Upper Respiratory Tract Infection.pdf
    302 – A Randomized Controlled Trial of Rapid Pathogen and Resistance Identification from Positive Blood Cultures.pdf
    68 – Tecovirimat for the Treatment of Mpox_ A Randomized Placebo-controlled Trial in the Democratic Republic of Congo (PALM007).pdf
    384 – National Trends and Racial Disparities in Sepsis-Related Mortality in Children in the United States, 1999-2019.pdf
    556 – The EMR and the ID physician.pdf
    228 – Should we invest in non-occupational post-exposure prophylaxis (nPEP) as a tool to end the HIV epidemic_ Con.pdf
    21 – What’s Hot in ID Clinical Sciences.pdf
    134 – Clinical Metagenomics_ Roadmap for the future.pdf
    154 – H5N1 Outbreak in Dairy Cattle_ Transmission and Natural History Studies.pdf
    602 – Non-traditional surveillance approaches for monitoring antimicrobial resistance and pathogens of global concern.pdf
    282 – Rheumatologic Mimickers of infectious Rashes.pdf
    53 – Local Metrics to Push Stewardship Programs Forward.pdf
    643 – Dynamic 11C-PABA PET_CT Imaging for Visualizing Pulmonary Mycobacteroides abscessus Infection_ Animal and Human studies.pdf
    633 – Incidence and Outcomes of Pediatric Allogeneic Hematopoietic Cell Transplant (allo-HCT) Recipients Under Surveillance and Not Under Surveillance for Human Adenovirus (HAdV) in the Post-HCT Period.pdf
    6 – Leveraging wastewater surveillance for respiratory virus infection response in healthcare facilities.pdf
    418 – Comparing the Effects of Commercial to Manual Initial Specimen Diversion Techniques (ISDT) on Clinical Outcomes and Institutional Costs.pdf
    630 – Sustained reduction of meropenem use in a tertiary-care pediatric service in Medell n, Colombia..pdf
    510 – Bacteriophages as Drug Delivery Vehicles for Polymyxin B.pdf
    230 – Advances and Challenges in Fungal Diagnostics.pdf
    252 – Leveraging the WHO FFX-Dx protocol to drive rapid diagnostic development and deployment.pdf
    291 – Precision Medicine in the Treatment of Fungal Infections.pdf
    261 – Updates in the Management of Leprosy Reactions.pdf
    19 – What’s Hot in HIV_ Clinical Sciences.pdf
    433 – Impact of Antibiotics on the Gut Microbiota_ Comparisons Using Model-Based Analyses.pdf
    579 – Safety and Immunogenicity of Mpox Vaccination in Adolescents.pdf
    424 – SARS-CoV-2 Positivity and Genetic Relationships among Cases within Households in the Cascadia Prospective Cohort Study, July 2022 to May 2023.pdf
    289 – Should I avoid piperacillin, tazobactam and vancomycin for patients at risk for acute kidney injury_.pdf
    89 – First-in-human study of a novel half-life extended monoclonal antibody (GB-0669) against SARS-CoV2 and related sarbecoviruses.pdf
    73 – Can Doxy-PEP Implementation Reverse Syphilis Trends_.pdf
    198 – Preparing Diverse Students for Successful Careers in ID.pdf
    345 – Opportunistic Infection Management_ New Aspects to an Old Foe.pdf
    605 – What Happens Outside, Affects Inside_ Controlling clusters of GAS in vulnerable healthcare settings.pdf
    131 – Vaccines Law_ Misinformation, and Experts.pdf
    454 – There s No Place Like Home_ OPAT Safety.pdf
    209 – Population Pharmacokinetics of Meropenem-Vaborbactam in Acutely Ill Hospitalized Patients with Various Degrees of Renal Dysfunction.pdf
    13 – Getting off the sidelines_ Promoting ID leadership in sepsis care.pdf
    598 – What s New with Management and Treatment of Pediatric Community-Acquired Pneumonia.pdf
    161 – Prospective Study of Cytomegalovirus (CMV) Reactivation in Patients with Multiple Myeloma Receiving anti-CD38 and BCMA Therapies_ An Interim Data Analysis.pdf
    482 – Host-Directed Therapy in Fungal Diseases.pdf
    167 – Phase 3, Randomized, Controlled Trial Evaluating Safety, Efficacy, and Pharmacokinetics (PK) of Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disea.pdf
    506 – Week 26 Interim Analysis of Implementation and Delivery of Long-Acting Injectable Cabotegravir for PrEP in a Community Pharmacy Setting.pdf
    410 – Evaluating the Evidence for Antimicrobial Stewardship in the OB_GYN Population.pdf
    639 – A Decade-Long Analysis of Ventilator-Associated Pneumonia in the Intensive Care Unit of a Public Hospital in a Major Brazilian City_ An Exploration of Trends, Challenges, and Opportunities.pdf
    582 – Feeling the Vibes_ An Investigation Into Resident Physician Antibiotic Prescribing Practices.pdf
    224 – Congenital Cytomegalovirus (CMV)_ Playing the Long Game.pdf
    137 – Spectrum and management of infectious diseases in newly resettled children.pdf
    3 – Diet, mucus and microbiome in cancer-related neutropenic fever.pdf
    207 – Ex vivo Assessment of Cefepime (FEP) Clearance during Continuous Renal Replacement Therapy (CRRT) and Clinical Validation of Optimized Dosing Regimens.pdf
    166 – Friday With the Health Care Epidemiology Pager.pdf
    281 – Skin Manifestations in Immunocompromised Children.pdf
    9 – Impact of Climate Change in the Immune Defense against Candida.pdf
    154 – H5N1 risk in Farm Workers_ The Colorado Experience.pdf
    495 – Integrating POC HCV RNA testing into mobile, syringe services, opioid treatment, and other high-impact programs.pdf
    519 – Antibodies Produced by Children with Kawasaki Disease (KD) Consistently Recognize Antigen in KD Tissues from the US and Japan.pdf
    60 – Using Psychological Safety to Create an Inclusive Learning Environment.pdf
    285 – A Look at a LEAP Year.pdf
    82 – Comparative Evaluation of Low Versus High Doses of Rifampin for the Treatment of Staphylococcal Bone and Joint Infections_ an open-label, randomized, controlled non-inferiority trial (EVRIOS).pdf
    625 – SARS-CoV-2 and Neuroimmunology.pdf
    391 – Modified Human Immunodeficiency Virus Testing Algorithm in Rural Missouri (MOdified HIV testing algorithm).pdf
    467 – Top Research Papers_ Yeasts.pdf
    547 – IWGDF_IDSA Guidelines on the diagnosis and treatment of diabetes-related foot infections.pdf
    571 – Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults = 65 Y.pdf
    637 – Stable bloodstream infection rates despite rising colonization_ Insights from a hospital system using in-house PCR screening for Candida auris.pdf
    363 – A case study in developing an in-house funded WGS surveillance program.pdf
    376 – 7 versus 14 days of Antibiotic Treatment for Patients with Bloodstream Infections.pdf
    622 – Prophylactic Antibiotics in Adults with Urinary Tract Infections_ Benefits and Harms.pdf
    260 – Benefits and Risks of Standard Multidrug Therapy versus Alternative Second-Line Drug Regimens for Hansen’s disease.pdf
    125 – Mind Blown_ Challenging HIV Clinical Cases.pdf
    190 – Increasing Access to Novel Therapeutics in Public Health Emergencies.pdf
    559 – Update on IE diagnosis.pdf
    509 – Pseudomonas aeruginosa-specific CRISPR-Cas3 bacteriophage cocktail developed to treat respiratory and bloodstream infections.pdf
    431 – Engraftment of donor derived anaerobic taxa and durable long-term multidrug resistant organism decolonization following fecal microbiota transplantation.pdf
    436 – Fidaxomicin isn’t necessary with Vancomycin and Bezlotuxumab_ Pro.pdf
    592 – Immunogenicity and Safety of High-dose versus Double-dose Quadrivalent Inactivated Influenza Vaccine in Adult Kidney Transplant Recipients_ A Randomized Controlled Trial.pdf
    149 – Invasive Fungal Infections Following Military and Civilian Trauma.pdf
    152 – Menopause and HIV Interactions.pdf
    154 – Pharmacokinetics and Safety of GS-1720 Following Multiple Ascending Doses in a Phase 1a Study in People Without HIV-1.pdf
    164 – Effectiveness of Adjuvanted Inactivated Influenza Vaccine versus High-Dose Inactivated Influenza Vaccine Against PCR-Confirmed Influenza among Adults =65 years_ A Pragmatic Randomized Study.pdf
    504 – Missed opportunities for HIV Prevention and Treatment in People Hospitalized with Serious Injection Related Infections_ The CHOICE+ Cohort.pdf
    138 – Theory and Practice of Dissemination and Implementation Science in Infectious Diseases.pdf
    303 – The A-Stop Study_ Rapid Tests for Candida Infection in Non-neutropenic Critically-ill Patients – A Multicentre Diagnostic Test Accuracy Study.pdf
    177 – AMR-Informed Antibiotic Use Metrics.pdf
    600 – Using large data and machine learning to identify intervention hot spots with a focus on improving antibiotic utilization.pdf
    77 – Preparing your Hospital_ From Identify, Isolate and Inform to Simulation and Training.pdf
    550 – Clinical Trials in Bacterial Diseases that may Change your Practice.pdf
    212 – Gonorrhea and Chlamydia Opt-Out Screening of Justice-Involved Females During Intake at the Los Angeles County Jail_ The Pivotal Role of Correctional Health Systems.pdf
    178 – Diagnostic Clinical Cases_ What Do I Do With This Test Result_.pdf
    195 – Using VR to Teach IPC Foundations and Cleaning and Disinfection of Portable Medical Equipment.pdf
    57 – Beta-lactamase Inhibitors_ Advancements, Challenges, and Opportunities.pdf
    512 – Efficacy of Gepotidacin versus Nitrofurantoin in a Nitrofurantoin Not Susceptible Population_ A Pooled Analysis of the EAGLE-2 and EAGLE-3 Randomized Controlled Trials in Uncomplicated Urinary Tract I.pdf
    170 – Intrapartum Antibiotic Exposure and Infectious Diseases in Childhood – A Population-based Cohort Study.pdf
    162 – Comparison of Clinical Risk Factors, Outcomes and Molecular Epidemiology of ESBL and non-ESBL Enterobacterales Bacteremia in Solid Organ Transplant Recipients.pdf
    515 – Neurological Complications in Children Hospitalized for Influenza, 2010 to 2022, the Canadian Immunization Monitoring Program Active (IMPACT).pdf
    409 – Targeting Tough Transplant Cases for Antimicrobial Stewardship.pdf
    407 – Emerging STIs in The Caribbean.pdf
    429 – SARS-CoV-2 Fecal Shedding Dynamics Among People with Symptomatic COVID-19.pdf
    146 – Is More Better_ Dosing of Antivirals in Patients with Obesity.pdf
    588 – The Association Between Contact Precautions for Methicillin-resistant Staphylococcus aureus (MRSA) Colonization and MRSA Bloodstream Infection (BSI) Rates in Los Angeles County Hospitals_ Results of a.pdf
    42 – Practical methods to enhance ID physician reimbursement.pdf
    215 – Trends in Syphilis and the Impact of the COVID-19 Pandemic in Florida_ A multiscale joinpoint regression analysis.pdf
    574 – Early Post-Marketing Safety Surveillance for the Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA).pdf
    75 – Bacterial AMR Detection.pdf
    189 – This is How we Do It_ US Approach to Antimicrobial Stewardship Guidelines.pdf
    12 – Optimizing Antibiotic Treatment and Stewardship for Patients with Sepsis.pdf
    44 – Current Treatment Approach for NTM lung Infection.pdf
    251 – Duration of treatment of infections caused by Pseudomonas aeruginosa and other non-fermenters in transplant or neutropenic patients_ an appraisal of current evidence.pdf
    246 – Spreading the Joy and Keeping it Fun_ Teaching in the Context of a Busy Clinical Practice.pdf
    367 – Enhancing antimicrobial stewardship capacity building and communication across multidisciplinary departments in Chinese hospitals_ a national qualitative study.pdf
    179 – INSPIRE Trial_ A 92-Hospital Cluster Randomized Trial of INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection versus Routine Antibiotic Selection Practices for Patients wi.pdf
    498 – Using Carrots Instead of Sticks_ How Policy Makers Can Promote IPC Practices in LTC.pdf
    503 – Antibiotic Mobile Application ABxSG – An Innovative and Effective Antibiotic Stewardship Tool that Improves Antibiotic Use and Reduces Healthcare Costs.pdf
    64 – Prediction Models 101_ The Data.pdf
    372 – Impact of Updated 2020 Public Health Service Guidelines on Deceased Organ Donors and Transplant Recipients.pdf
    73 – Bridging the Treatment Gap_ Estimating the Impact of Widespread Syphilis Point-of-Care Testing.pdf
    160 – RSV Pre-F IgG levels in pediatric hematopoietic stem cell transplant (HCT) and leukemia_lymphoma patients.pdf
    609 – Management of Substance Use Disorders in HIV clinic.pdf
    208 – Challenging Vaccine Issues_ Beyond the Guidelines.pdf
    185 – TB After 3HP_ Assessing the durability of TB prevention in a high-incidence island.pdf
    400 – Klebsiella Pneumoniae Blood Stream Infection_ Host Factors and Immunity.pdf
    456 – Optimizing LAI Patient Care and Program Features.pdf
    501 – Impact of Implementation of World Health Organization (WHO) National Action Plans (NAP) on Antibiotic Rates_ A Time Series Analysis of 38 Countries.pdf
    50 – Linking CNS Infection and Inflammation with Neurodegeneration.pdf
    366 – Antibiotic Stewardship Program Improved the Susceptibility of Commonly Seen Gram-negative Bacilli Over 12 Years at Singapore General Hospital.pdf
    353 – Host biomarkers for infectious diseases diagnosis_ What s current and what s coming.pdf
    11 – Bundles and beyond_ What works and doesn t work in improving sepsis outcomes.pdf
    197 – Being INSPIREd_ My Experience in an Undergraduate ID Summer Program.pdf
Videos+PDFs+Case studis
Related products
$10
Uncategorized
$10
Uncategorized
$30
Uncategorized
$10
Uncategorized
$10
Uncategorized
$10
Uncategorized
$10